Posters

iStent insertion in patients with cataracts and complex glaucoma: 1 year results

Poster Details

First Author: M.Kutubi UK

Co Author(s):    P. Pandey   G. Moussa   A. Mandalos   I. Masood     

Abstract Details

Purpose:

iStent® is an innovative device designed to be implanted into Schlemm's canal via an ab interno approach. We report one-year outcomes of iStent implantation with or without cataract surgery in a series of complex glaucoma patients.

Setting:

Birmingham and Midland Eye Centre, Birmingham, UK

Methods:

Ongoing, prospective, interventional case series involving 37 patients with complex disease.

Results:

Total 37 patients. 20 males, 17 females, mean age 70.3 years. Diagnoses - 22 primary open angle glaucoma (POAG) including one patient with Juvenile open angle glaucoma, 5 ocular hypertension, 2 pigmentary glaucoma, 2 pseudoexfoliation, 1 uveitics, 1 post trauma and 4 primary angle closure. One POAG patient had Marfans syndrome and lens dislocation, had been fitted with a scleral-fixated intraocular lens in his only eye. One pseudophakic patient with a history of capsular phimosis and YAG laser anterior capsulotomy had developed medically uncontrolled inflammatory glaucoma as a result of retained anterior capsule remnants in the anterior chamber. Another patient had an iStent implanted in addition to surgical iridectomy in for uveitis and angle closure glaucoma due to posterior synechiae. Eight patients had previous glaucoma surgery. Seven patients had advanced disease. Mean (range) preoperative IOP 24 (11-46) mmHg on a mean of 3.1 medications (0-5). Mean 1 year IOP was reduced to 16.3 (11-24) on a mean of 1.9 medications (0-4). IOP measurement at last follow up at 12 months was 16.2 mmHg (range 14-20mmHg). No intraoperative complications noted and blood reflux seen in all cases, which was a reliable sign of proper placement of the device.

Conclusions:

The iStent® is effective and safe option for selected patients with complex glaucoma at the one year stage. FINANCIAL INTEREST: One of more of the authors... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented